Pfizer announces FDA approval of meningococcal disease vaccine

Pfizer announced that the Food and Drug Administration has approved Penbraya, the first pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age. Penbraya combines the components from two meningococcal vaccines, Trumenba and Nimenrix “to help protect against the five most common meningococcal serogroups that cause the majority of invasive meningococcal disease globally,” the company said in a statement. The CDC Advisory Committee on Immunization Practices will meet on October 25 to discuss recommendations for the appropriate use of Penbraya in adolescents and young adults.